<DOC>
	<DOCNO>NCT02352558</DOCNO>
	<brief_summary>This multicenter , open label , Phase 1 dose-escalation study BBI608 administer patient relapse , refractory hematologic malignancy , include multiple myeloma , lymphoma , others .</brief_summary>
	<brief_title>A Study BBI608 Adult Patients With Advanced , Refractory Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Major 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) accordance local regulatory requirement 2 . A histologically confirm hematologic malignancy advance , relapse , refractory standard , currently available anticancer treatment option 3 . ≥ 18 year age 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 dose escalation phase ≤ 2 dose expansion phase 5 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last dose 6 . Females childbearing potential must negative serum pregnancy test 7 . Aspartate transaminase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) . Patients whose disease involve liver laboratory value AST ≤ 3.5 ULN , AST ≤ 3.5 ULN , albumin ≥ 35g/L may enrol agree upon Principal Investigator Medical Monitor Sponsor 8 . Total bilirubin &lt; 1.5 x ULN , except case elevation total bilirubin due elevate level unconjugated bilirubin consistent diagnosis Gilbert 's Syndrome 9 . Life expectancy ≥ 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelo-Dysplastic Syndrome</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>